AZMACORT (triamcinolone acetonide) by AbbVie is clinical pharmacology: topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. Approved for diabetic macular edema, acute gout, uveitis and 3 more indications. First approved in 1982.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AZMACORT (triamcinolone acetonide) is a topical/inhaled corticosteroid that reduces inflammation, pruritus, and vasodilation through glucocorticoid receptor binding. Delivered as a metered-dose aerosol inhalation, it treats allergic rhinitis, asthma, atopic dermatitis, uveitis, acute gout, diabetic macular edema, and otitis media. The drug works by inhibiting multiple inflammatory cell types and mediators involved in allergic and inflammatory responses.
As a mature product approaching loss of exclusivity with low competitive pressure (30/100), career opportunities are likely limited to maintenance roles rather than growth-oriented positions.
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Worked on AZMACORT at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on AZMACORT offers stability in a mature, established product portfolio but limited growth opportunities due to approaching LOE and competitive pressure from newer mechanisms. Career advancement would typically require lateral movement to growth-stage products such as RINVOQ or emerging indications rather than vertical growth within this brand.